A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first complete remission
Daniele Avenoso, Vera Radici, Alessandro Leoni, Cristina Skert, Massimo Martino, Nicola Mordini, Francesco Saraceni, Attilio Olivieri, Fabio Ciceri, Cristina Tecchio, Alessandra Picardi, Giorgia Saporiti, Francesca Patriarca, Paola Bresciani, Chiara Nozzoli, Denise Maravalle, Nicola Polverelli, Gabriele Magliano, Enrico Morello, Mirko Farina, Simona Bernardi, Federica Re, Luca Garuffo, Simone Maifredi, Silvia Zanon, Rachele De Domenico, Michele Malagola, Domenico Russo · 2026
Read A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first complete remission by Daniele Avenoso, Vera Radici, Alessandro Leoni, Cristina Skert, Massimo Martino, Nicola Mordini, Francesco Saraceni, Attilio Olivieri, Fabio Ciceri, Cristina Tecchio, Alessandra Picardi, Giorgia Saporiti, Francesca Patriarca, Paola Bresciani, Chiara Nozzoli, Denise Maravalle, Nicola Polverelli, Gabriele Magliano, Enrico Morello, Mirko Farina, Simona Bernardi, Federica Re, Luca Garuffo, Simone Maifredi, Silvia Zanon, Rachele De Domenico, Michele Malagola, Domenico Russo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13569411.txt.
Description
Daniele Avenoso leads a 2026 phase II multicenter trial of a gentler high-dose conditioning regimen, treosulfan plus fludarabine, before donor stem cell transplant. Patients were adults aged forty to sixty-five with acute myeloid leukemia in first remission. Eighty-two patients were followed for a median of about twenty months to judge leukemia-free survival and safety against standard harsher regimens.
About eighty-two percent remained leukemia-free at one year, and relapse by one year was under fifteen percent. Donors were mostly matched unrelated volunteers. Safety was described as excellent in the results available. The regimen offers transplant centers a less toxic preparation that still protects against leukemia returning.
Catalog record
| CREATOR | Daniele Avenoso, Vera Radici, Alessandro Leoni, Cristina Skert, Massimo Martino, Nicola Mordini, Francesco Saraceni, Attilio Olivieri, Fabio Ciceri, Cristina Tecchio, Alessandra Picardi, Giorgia Saporiti, Francesca Patriarca, Paola Bresciani, Chiara Nozzoli, Denise Maravalle, Nicola Polverelli, Gabriele Magliano, Enrico Morello, Mirko Farina, Simona Bernardi, Federica Re, Luca Garuffo, Simone Maifredi, Silvia Zanon, Rachele De Domenico, Michele Malagola, Domenico Russo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29870 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |